The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma.
A novel chelating derivative of alpha melanocyte stimulating hormone, bis MSH-DTPA, has been used for the diagnostic targeting of malignant melanoma. 15 patients were investigated of whom nine were shown by other means to have active disease at the time of the scan. Tumours were imaged in all of these nine patients. Of a total of 46 lesions over 10 mm encountered, 41 (89%) were imaged. There were no false positives and in two cases bisMSH-DTPA was instrumental in reversing diagnoses made using ultrasound. Derivatives of melanocyte stimulating hormone may be of considerable value in targeting melanomas.
Wraight
E P
EP
Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge, UK.
Bard
D R
DR
Maughan
T S
TS
Knight
C G
CG
Page-Thomas
D P
DP
D000328:Adult; D000368:Aged; D002614:Chelating Agents; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis; D008297:Male; D009074:Melanocyte-Stimulating Hormones; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000556:secondary; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010157:Palatal Neoplasms / Q000000981:diagnostic imaging; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging
D002614:Chelating Agents; D007205:Indium Radioisotopes; D004369:Pentetic Acid; D009074:Melanocyte-Stimulating Hormones